FDA cardiovascular indication for semaglutide led to short-term uptake but persistent treatment gaps among high-risk patients, new Truveta study finds

by Ellie Lampton | Feb 10, 2026

BELLEVUE, Wash.—February 10, 2026—A new peer-reviewed study led by Truveta Research and collaborators finds that the US Food and Drug Administration’s (FDA) March 2024 expansion of semaglutide’s cardiovascular indication was followed by a rapid but short-lived...

Truveta deepens regulatory science leadership with appointment of John D. Seeger, PharmD, DrPH, FISPE as Senior Vice President of Evidence Services

by Ellie Lampton | Feb 9, 2026

Globally recognized pharmacoepidemiologist brings decades of experience advancing real-world evidence for regulatory decision-making. BELLEVUE, Wash.—February 9, 2026—Truveta today announced the appointment of John D. Seeger, PharmD, DrPH, FISPE, a global leader in...

Truveta Research study published in Contraception advances understanding of women’s health and clinical guideline adoption

by Ellie Lampton | Feb 2, 2026

BELLEVUE, Wash.—February 2, 2026—Truveta today announced the publication of a new Truveta Research study in Contraception, a leading peer-reviewed journal in reproductive health. The study leverages real-world data to examine trends in pain management during...

Truveta launches real-time clinical trials solution to accelerate study design, enrollment, and evidence generation

by Ellie Lampton | Jan 27, 2026

Bellevue, WA — January 27, 2026 — Truveta today announced the launch of its new clinical trials solution that enables trial sponsors to design, optimize, and execute clinical studies using the most complete, daily refreshed real-world data in the United States. Built...

Truveta deepens oncology and scientific leadership with appointment of Johnathan Lancaster, MD, PhD as President and Chief Scientific Officer

by Ellie Lampton | Jan 26, 2026

Veteran physician–scientist brings decades of experience advancing oncology and genomics research across industry and academia. BELLEVUE, Wash. — January 26, 2026 — Truveta today announced the appointment of Johnathan M. Lancaster, MD, PhD as President and Chief...